Description

Perjeta 420mg Injection (Pertuzumab) – Uses, Side Effects, Dosage & Price in Pakistan

Perjeta 420mg Injection (Pertuzumab) is a prescription targeted cancer medicine used as part of combination treatment for certain HER2-positive breast cancers. Pertuzumab is a HER2/neu receptor antagonist that works by blocking HER2 signaling involved in the growth and survival of cancer cells. It is administered by intravenous infusion under the supervision of a qualified healthcare professional.

Perjeta 420mg Injection is used together with other cancer medicines, particularly trastuzumab and chemotherapy, according to the patient’s diagnosis and treatment setting. For patients in Pakistan looking for information about Perjeta, it is important to understand its approved uses, dosage, possible side effects, precautions, and monitoring requirements. Impo Medic provides medicine information to help patients understand prescription oncology treatments before discussing them with their healthcare team.

Perjeta 420mg Injection (Pertuzumab) Used For

Perjeta is indicated for adults with certain HER2-positive breast cancers.

It may be used:

• With trastuzumab and docetaxel for HER2-positive metastatic breast cancer in patients who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease.
• With trastuzumab and chemotherapy as neoadjuvant treatment for HER2-positive, locally advanced, inflammatory, or certain early-stage breast cancers.
• With trastuzumab and chemotherapy as adjuvant treatment for adults with HER2-positive early breast cancer who have a high risk of recurrence.

Treatment selection requires confirmation of HER2 status using an appropriate validated test.

HER2-Positive Breast Cancer

HER2 is a protein that can be present at higher-than-normal levels on some breast cancer cells. HER2-positive cancers may respond to medicines designed to specifically interfere with HER2 signaling.

Pertuzumab targets HER2 and is generally used as part of a combination regimen rather than as a stand-alone treatment for the approved breast cancer indications.

How Perjeta 420mg Injection (Pertuzumab) Works

Pertuzumab is a monoclonal antibody and HER2/neu receptor antagonist. It binds to a specific region of the HER2 receptor and interferes with HER2-related signaling.

HER2 signaling can contribute to cancer-cell growth and survival. By blocking this pathway, pertuzumab helps disrupt signals that support the growth of HER2-positive cancer cells.

Perjeta is commonly combined with trastuzumab because the two medicines target different areas of the HER2 receptor. The combination is used with chemotherapy according to the treatment plan established by the oncologist.

Perjeta 420mg Injection Dosage

Perjeta is given only by intravenous infusion. It must not be administered as an IV push or bolus.

The labeled dosing schedule is:

• Initial dose: 840 mg by IV infusion over approximately 60 minutes.
• Maintenance dose: 420 mg by IV infusion over approximately 30–60 minutes every 3 weeks.

The 420mg Perjeta vial contains 420mg of pertuzumab in 14mL at a concentration of 30mg/mL. It is supplied as a single-dose vial and requires dilution before intravenous administration.

The exact treatment regimen depends on whether Perjeta is being used for metastatic, neoadjuvant, or adjuvant treatment and which other medicines are included.

Patients should never attempt to calculate or administer Perjeta themselves. It should be prepared and administered by trained healthcare professionals.

How Perjeta 420mg Injection Is Given

Perjeta is administered through an intravenous infusion in a medical setting.

Before treatment, the healthcare team evaluates factors such as:

• HER2 status
• Heart function
• Pregnancy status when applicable
• Previous cancer treatments
• Current medicines
• Overall medical condition

Heart function, particularly left ventricular ejection fraction (LVEF), should be assessed before starting treatment and monitored regularly during therapy.

If a scheduled dose is delayed, the appropriate dosing approach depends on the length of time since the previous dose. The prescribing information provides specific instructions for intervals of less than or at least 6 weeks.

Perjeta 420mg Injection Side Effects

Perjeta can cause side effects, particularly when administered with trastuzumab and chemotherapy.

Possible side effects include:

• Diarrhea
• Hair loss
• Nausea
• Fatigue
• Rash
• Vomiting
• Reduced appetite
• Headache
• Weakness
• Muscle or joint pain
• Infusion-related reactions
• Low blood-cell counts when used with chemotherapy

The likelihood and severity of side effects can vary according to the treatment combination and individual patient.

Patients should inform their healthcare team if side effects become severe, persistent, or interfere with daily activities.

Serious Side Effects and Warnings

Perjeta has important warnings concerning left ventricular dysfunction and embryo-fetal toxicity.

Heart Problems

Perjeta can cause a decrease in left ventricular function and may contribute to congestive heart failure. Patients may require heart-function assessments before and during treatment.

Seek medical attention promptly if symptoms such as:

• New or worsening shortness of breath
• Swelling of the ankles or legs
• Swelling of the face
• Palpitations
• Rapid weight gain
• Dizziness
• Fainting

develop during treatment.

Infusion-Related Reactions

Perjeta can cause infusion-related reactions. Patients are monitored during and after administration for symptoms such as fever, chills, breathing difficulties, headache, nausea, or other signs of an infusion reaction.

Severe hypersensitivity or anaphylaxis can also occur.

Embryo-Fetal Toxicity

Exposure to Perjeta can cause fetal harm, including embryo-fetal death and birth defects. Pregnancy status should be verified before treatment in females of reproductive potential. Effective contraception is recommended during treatment and for 7 months after the last dose when Perjeta is used in combination with trastuzumab.

Precautions Before Using Perjeta

Before starting Perjeta 420mg Injection, tell your healthcare provider about your complete medical history.

Special attention may be required if you have:

• Previous heart disease
• Reduced heart function
• Previous treatment with medicines that may affect the heart
• A history of serious allergic reactions
• Pregnancy or plans to become pregnant
• Current breastfeeding
• Previous cancer treatments

Your oncologist may order cardiac assessments and other tests before and during treatment.

Perjeta should not be given to patients with known hypersensitivity to pertuzumab or any of its ingredients.

Perjeta 420mg Injection Drug Interactions

Perjeta is commonly administered as part of a combination cancer-treatment regimen. Its use alongside trastuzumab and chemotherapy is based on the specific cancer treatment plan.

Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins, and supplements you are taking.

Do not add or stop another medicine without discussing it with your healthcare provider, particularly during active cancer treatment.

Perjeta 420mg Injection During Pregnancy

Perjeta can cause serious fetal harm. Women who are pregnant, planning pregnancy, or who could become pregnant should discuss this with their healthcare provider before receiving treatment.

Pregnancy testing is recommended before starting Perjeta in females of reproductive potential. Effective contraception should be used during treatment and for 7 months after the last dose when Perjeta is used with trastuzumab.

If pregnancy occurs during treatment or within the relevant post-treatment period, the treating healthcare professional should be contacted promptly.

Perjeta 420mg Injection Storage

Perjeta 420mg Injection should be stored under controlled conditions by the healthcare facility or pharmacy.

According to the current prescribing information:

• Store refrigerated at 2°C to 8°C (36°F to 46°F).
• Keep the vial in its original carton to protect it from light.
• Do not freeze.
• Do not shake.

The medicine is supplied as a 420mg/14mL single-dose vial and should be prepared for infusion according to professional instructions.

Perjeta 420mg Injection Price in Pakistan

The price of Perjeta 420mg Injection in Pakistan can vary depending on the supplier, manufacturer, availability, import conditions, and market fluctuations.

Because Perjeta is a specialized oncology medicine, its price may be considerably different between suppliers. Patients should confirm the current price, packaging, strength, and availability before purchasing.

For Pakistan-based medicine information and availability, patients can contact Impo Medic to check the current product details.

The exact price should always be confirmed before placing an order because oncology medicine prices can change according to market availability.

How to Buy Perjeta 420mg Injection in Pakistan

Patients looking to buy Perjeta 420mg Injection in Pakistan should obtain it through a reliable medicine supplier and according to a valid prescription from their healthcare professional.

When purchasing Perjeta, confirm:

• Product name
• Pertuzumab strength
• 420mg/14mL vial presentation
• Manufacturer and packaging
• Batch and expiry information
• Proper storage conditions
• Authenticity of the medicine

Impo Medic can be contacted for information about Perjeta availability in Pakistan. Since this is an intravenous oncology medicine, it should only be administered by trained healthcare professionals in an appropriate medical setting.

Frequently Asked Questions About Perjeta 420mg Injection (Pertuzumab)

What is Perjeta 420mg Injection (Pertuzumab) used for?

Perjeta is used with other cancer medicines for certain HER2-positive breast cancers, including metastatic breast cancer and selected early-stage or locally advanced breast cancers.

Is Perjeta a chemotherapy medicine?

Perjeta is a targeted monoclonal antibody rather than a traditional cytotoxic chemotherapy drug. It targets the HER2 receptor and is commonly used together with trastuzumab and chemotherapy in approved treatment regimens.

What is the usual maintenance dose of Perjeta?

The labeled maintenance dose is 420mg every 3 weeks, administered by intravenous infusion over approximately 30–60 minutes. The initial dose is 840mg over approximately 60 minutes.

How is Perjeta 420mg Injection administered?

Perjeta is administered through an intravenous infusion. It must not be given as an IV push or bolus. Administration should be performed by qualified healthcare professionals.

Does Perjeta affect the heart?

Yes. Perjeta can cause left ventricular dysfunction and heart failure. Heart function should be evaluated before treatment and monitored at regular intervals during therapy.

Can Perjeta cause an allergic reaction?

Yes. Infusion-related reactions, hypersensitivity, and anaphylaxis can occur. Patients are monitored during treatment, and serious symptoms such as breathing difficulty or chest pain require immediate medical attention.

Can Perjeta be used during pregnancy?

Perjeta can cause serious fetal harm and should not be used during pregnancy unless specifically determined appropriate by the treating healthcare team. Effective contraception is recommended during treatment and for 7 months after the last dose when used with trastuzumab.

How should Perjeta 420mg Injection be stored?

Perjeta should be refrigerated at 2°C to 8°C, kept in its original carton, protected from light, and should not be frozen or shaken.